Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes

Philippe Thuillier,1 Zarrin Alavi,2 Véronique Kerlan1 1Department of Endocrinology, Diabetology and Metabolic Diseases, 2French Institute of Health and Medical Research CIC 1412, Medical University Hospital of Brest La Cavale Blanche, Brest, France Abstract: Insulin degludec (IDeg) is a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Thuillier P, Alavi Z, Kerlan V
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/584ab66d395a424ba60b9ee8664e6ab1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:584ab66d395a424ba60b9ee8664e6ab1
record_format	dspace
spelling	oai:doaj.org-article:584ab66d395a424ba60b9ee8664e6ab12021-12-02T03:38:47ZLong-term safety and efficacy of insulin degludec in the management of type 2 diabetes1178-7007https://doaj.org/article/584ab66d395a424ba60b9ee8664e6ab12015-10-01T00:00:00Zhttps://www.dovepress.com/long-term-safety-and-efficacy-of-insulin-degludec-in-the-management-of-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Philippe Thuillier,1 Zarrin Alavi,2 Véronique Kerlan1 1Department of Endocrinology, Diabetology and Metabolic Diseases, 2French Institute of Health and Medical Research CIC 1412, Medical University Hospital of Brest La Cavale Blanche, Brest, France Abstract: Insulin degludec (IDeg) is a novel antiglycemic agent belonging to the therapeutic class of ultra-long duration basal insulin analogs. Its half-life and duration of action are 25 hours and 42 hours, respectively. This pharmacodynamic profile leads to a strict dosing schedule, ie, IDeg is injected at the same time each day to ensure optimal biological action and consistent glycemic control. According to the literature, IDeg provides glycemic control and nocturnal hypoglycemia reduction comparable with other long-acting analogs in type 2 diabetes mellitus. The risk of severe hypoglycemic episodes seems also to be reduced when using IDeg therapy; however, long-term follow-up is warranted for monitoring of possible but relatively infrequent adverse events. IDeg is also available in combination with aspart insulin and with liraglutide. The above preparations have been approved by the European Medicines Agency and other national health authorities. In 2012, the US Food and Drug Administration asked for a complementary study on IDeg-associated cardiovascular risk. Future prospective evaluation of large cohorts of patients with type 2 diabetes mellitus treated with IDeg, with long-term follow-up, can provide further relevant information on the safety of IDeg therapy. Keywords: degludec insulin, hypoglycemia, HbA1c, safety, type 2 diabetes mellitus, basal insulin analogThuillier PAlavi ZKerlan VDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2015, Iss default, Pp 483-493 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Thuillier P Alavi Z Kerlan V Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
description	Philippe Thuillier,1 Zarrin Alavi,2 Véronique Kerlan1 1Department of Endocrinology, Diabetology and Metabolic Diseases, 2French Institute of Health and Medical Research CIC 1412, Medical University Hospital of Brest La Cavale Blanche, Brest, France Abstract: Insulin degludec (IDeg) is a novel antiglycemic agent belonging to the therapeutic class of ultra-long duration basal insulin analogs. Its half-life and duration of action are 25 hours and 42 hours, respectively. This pharmacodynamic profile leads to a strict dosing schedule, ie, IDeg is injected at the same time each day to ensure optimal biological action and consistent glycemic control. According to the literature, IDeg provides glycemic control and nocturnal hypoglycemia reduction comparable with other long-acting analogs in type 2 diabetes mellitus. The risk of severe hypoglycemic episodes seems also to be reduced when using IDeg therapy; however, long-term follow-up is warranted for monitoring of possible but relatively infrequent adverse events. IDeg is also available in combination with aspart insulin and with liraglutide. The above preparations have been approved by the European Medicines Agency and other national health authorities. In 2012, the US Food and Drug Administration asked for a complementary study on IDeg-associated cardiovascular risk. Future prospective evaluation of large cohorts of patients with type 2 diabetes mellitus treated with IDeg, with long-term follow-up, can provide further relevant information on the safety of IDeg therapy. Keywords: degludec insulin, hypoglycemia, HbA1c, safety, type 2 diabetes mellitus, basal insulin analog
format	article
author	Thuillier P Alavi Z Kerlan V
author_facet	Thuillier P Alavi Z Kerlan V
author_sort	Thuillier P
title	Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
title_short	Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
title_full	Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
title_fullStr	Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
title_full_unstemmed	Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
title_sort	long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/584ab66d395a424ba60b9ee8664e6ab1
work_keys_str_mv	AT thuillierp longtermsafetyandefficacyofinsulindegludecinthemanagementoftype2diabetes AT alaviz longtermsafetyandefficacyofinsulindegludecinthemanagementoftype2diabetes AT kerlanv longtermsafetyandefficacyofinsulindegludecinthemanagementoftype2diabetes
_version_	1718401662541889536

Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes

Ejemplares similares